2,4-dichlorobenzoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2,4-dichlorobenzoic acid : A chlorobenzoic acid that is benzoic acid in which the ring hydrogens at positions 2 and 4 are substituted by chloro groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5787 |
| CHEMBL ID | 1492029 |
| CHEBI ID | 30748 |
| SCHEMBL ID | 111279 |
| MeSH ID | M0192481 |
| Synonym |
|---|
| BB 0240623 |
| 2,4-dichloro-benzoic acid |
| CHEBI:30748 , |
| benzoic acid, 2,4-dichloro- |
| einecs 200-067-8 |
| ai3-14873 |
| brn 1868192 |
| nsc 578 |
| AG-617/02198062 |
| NCGC00091214-01 |
| STK297837 |
| C06670 , |
| nsc-578 |
| 2,4-dichlorobenzoic acid |
| 50-84-0 |
| nsc578 |
| wln: qvr bg dg |
| inchi=1/c7h4cl2o2/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3h,(h,10,11 |
| 2,4-dichlorobenzoic acid, 98% |
| D0337 |
| BMSE000672 |
| AKOS000119754 |
| A23852 |
| NCGC00091214-02 |
| dtxcid104977 |
| cas-50-84-0 |
| tox21_200756 |
| NCGC00258310-01 |
| dtxsid0024977 , |
| 0sr0320d45 , |
| unii-0sr0320d45 |
| ccris 9472 |
| FT-0610044 |
| AM20050123 |
| CHEMBL1492029 |
| AB01333124-02 |
| 2,4 dichlorobenzoic acid |
| SCHEMBL111279 |
| furosemide impurity e [ep impurity] |
| dichlorobenzoic acid, 2,4- |
| PS-4049 |
| 2,4-dichlorobenzoicacid |
| W-105928 |
| STR01599 |
| AC-22899 |
| F2191-0069 |
| mfcd00002414 |
| 2,4-dichlorobenzoic acid, pestanal(r), analytical standard |
| 2,4-dichlorobenzoic acid; furosemide imp. e (ep); 2,4-dichlorobenzyl alcohol impurity e; furosemide impurity e |
| Z57127531 |
| CS-W013226 |
| NCGC00091214-03 |
| Q27104142 |
| EN300-18039 |
| SY007062 |
| D77744 |
| PD163264 |
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| chlorobenzoic acid | Any member of the class of benzoic acids in which the benzene ring is substituted by at least one chloro group. |
| dichlorobenzene | Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.1000 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 70.1970 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 3.9811 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 78.7624 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 53.0804 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.5893 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 39.8107 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 78.7624 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||